中文摘要：

临床上经典药物酪氨酸激酶抑制剂（TKI）为治疗慢性髓性白血病开辟了新途径,可以改善患者临床治疗效果及预后,甚至与同年龄段健康人生存年龄没有差异.它是通过不同通路、细胞分子诱导细胞凋亡从而治疗白血病.随着药物治疗过程及病情进展,耐药事件时有发生,耐药的发生主要与BCR-ABL1点突变及BCR-ABL基因扩增有关.不同突变导致不同耐药水平、临床结局各异.分析目前慢性髓性白血病耐药机制及治疗策略,早期选择靶向药物TKI、联合用药优化治疗方案,避免耐药发生,为改善患者预后,延长生存期,提高生活质量提供一个思路。

英文摘要：

Tyrosine kinase inhibitors (TKI), as classic drugs, by inducing cell apoptosis, is a new approach to therapy chronic myelogenous leukemia through different pathways and cell molecule in clinic. It can improve patient clinical outcomes and prognosis, even with the same age life period compared to that of the same age. Along with the progress in the medication process and disease, drugs resistance events have occurred, mainly with the bcr-abl1 point mutations and BCR-ABL gene amplification. Different mutations can lead to different drug resistance level, which leads to different clinical outcomes. Analysis of the current drug resistance and treatment strategies in chronic myeloid leukemia, which is in order to early choose targeted TKI, combine usage of drugs and provide a optimizing therapeutic strategy. Therefore it can avoid drug resistance, improve clinical outcomes and prognosis, prolong the survival period, and improve the quality of life to provide a train of thought.